Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche Reports Positive Phase I Results For CT-388 In Obesity
Details : CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist, which is being developed for the treatment of obesity and type 2 diabetes.
Product Name : CT-388
Product Type : Peptide
Upfront Cash : Inapplicable
May 16, 2024
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CDX-7108
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Codexis
Deal Size : $50.0 million
Deal Type : Agreement
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
Details : Through agreement, Nestlé Health Science will be solely responsible for the continued development and commercialization of CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency (EPI).
Product Name : CDX-7108
Product Type : Enzyme
Upfront Cash : $5.0 million
December 27, 2023
Lead Product(s) : CDX-7108
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Codexis
Deal Size : $50.0 million
Deal Type : Agreement
Lead Product(s) : Octreotide Acetate,Lanreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Debio 4126 (octreotide) is a synthetic octapeptide that mimics the pharmacology of endogenous somatostatin (SST). It demonstrates activity against growth hormone and glucagon, treating the disordered tissue growth and insulin regulation in patients with ...
Product Name : Debio 4126
Product Type : Peptide
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Octreotide Acetate,Lanreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable